The RDI Fund seeks to bridge the 'valley of death' in technology commercialisation. Evaluate its design and challenges.

The "valley of death" is the stage where a laboratory-validated technology fails to attract capital before market deployment. The ₹1 lakh crore Research, Development and Innovation (RDI) Scheme, approved by the Cabinet on 1 July 2025, targets precisely this gap [1]. Its financing design is sound; its delivery architecture remains unproven.

Design strengths

• Patient, risk-tolerant capital: long-tenor financing at low or nil interest, largely unsecured, with equity for startups — filling the space commercial banks avoid [1].
• Two-tier architecture: a Special Purpose Fund within ANRF acts as custodian, disbursing through Second-Level Fund Managers such as TDB and BIRAC, placing domain appraisal closer to the innovator [1][2].
• Stage-targeted eligibility: projects at TRL-4 and above, with up to 50% of assessed cost financed, so public money crowds in private capital rather than substituting it [3].
• Demonstrated traction: TDB's September 2026 agreement with GalaxEye commits ₹63.84 crore in a ₹247.69 crore project to carry indigenous OptoSAR (SAR + electro-optical fusion) satellite technology from TRL-6 to TRL-9 [4].
• Strategic focus on sunrise domains — deep tech, space, AI, biotechnology, energy transition [1].

Challenges

• Thin deal flow: national R&D remains predominantly government-funded, and few firms maintain TRL-4+ pipelines, risking under-absorption of the corpus.
• Institutional bandwidth: TDB, historically a small lender offering 5% simple-interest loans, must now appraise equity and debenture-type deep-tech exposures at far greater scale [5].
• Deployment lag: operational guidelines and SLFM allocations followed the Cabinet nod only after months [2]; slow disbursal blunts relevance in fast-moving technologies.
• Exit uncertainty: convertible-instrument stakes in unlisted deep-tech firms lack ready exits, and the valley may reappear at the scale-up stage absent assured public procurement.
• Accountability diffusion across two tiers demands transparent selection and outcome metrics.

On balance, the RDI Fund is a well-conceived instrument correcting a real market failure in innovation finance. Its success now depends on speed of disbursal, SLFM capacity-building, and pairing funding with demand-side assurance — converting India's research strength into commercial and strategic self-reliance.